GlassScriptPhysician profile
Kamrul Islam
NPI 1245490010
$969.63
in general payments reported to CMS, 2019-2025
15 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.55 · 2020: $222 · 2021: $22.93 · 2022: $83.89 · 2023: $201 · 2024: $222 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $196.82 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $146.60 | 2019-2024 | Dificid, Zerbaxa |
| Astrazeneca Pharmaceuticals LP | $139.52 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $134.04 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.63 | 2020-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $57.93 | 2019-2023 | Eliquis |
| Novo Nordisk INC | $45.05 | 2024-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $35.67 | 2020 | |
| Astellas Pharma US INC | $27.51 | 2025 | Cresemba |
| Abbott Laboratories | $21.99 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.90 | 2023 | Jardiance |
| Amgen INC. | $20.82 | 2025 | Repatha |
| Philips North America LLC | $19.06 | 2019 | |
| Medtronic Vascular, INC. | $18.68 | 2019 | |
| Boston Scientific Corporation | $14.41 | 2023 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamrul Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.